These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 36717500)

  • 1. Aquaporins in Diabetes Insipidus.
    Lu HAJ; He J
    Adv Exp Med Biol; 2023; 1398():267-279. PubMed ID: 36717500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diabetes Insipidus.
    Lu HA
    Adv Exp Med Biol; 2017; 969():213-225. PubMed ID: 28258576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New developments and concepts in the diagnosis and management of diabetes insipidus (AVP-deficiency and resistance).
    Angelousi A; Alexandraki KI; Mytareli C; Grossman AB; Kaltsas G
    J Neuroendocrinol; 2023 Jan; 35(1):e13233. PubMed ID: 36683321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [From genes to disease: from vasopressin-V2-receptor and aquaporine-2 to nephrogenic diabetes insipidus].
    Knoers NV; Deen PM
    Ned Tijdschr Geneeskd; 2000 Dec; 144(50):2402-4. PubMed ID: 11145096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vasopressin-independent targeting of aquaporin-2 by selective E-prostanoid receptor agonists alleviates nephrogenic diabetes insipidus.
    Olesen ET; Rützler MR; Moeller HB; Praetorius HA; Fenton RA
    Proc Natl Acad Sci U S A; 2011 Aug; 108(31):12949-54. PubMed ID: 21768374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic deletion of the nuclear factor of activated T cells 5 in collecting duct principal cells causes nephrogenic diabetes insipidus.
    Petrillo F; Chernyakov D; Esteva-Font C; Poulsen SB; Edemir B; Fenton RA
    FASEB J; 2022 Nov; 36(11):e22583. PubMed ID: 36197017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AKAPs-PKA disruptors increase AQP2 activity independently of vasopressin in a model of nephrogenic diabetes insipidus.
    Ando F; Mori S; Yui N; Morimoto T; Nomura N; Sohara E; Rai T; Sasaki S; Kondo Y; Kagechika H; Uchida S
    Nat Commun; 2018 Apr; 9(1):1411. PubMed ID: 29650969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of AQP2 water channels by protein kinase A: therapeutic strategies for congenital nephrogenic diabetes insipidus.
    Ando F
    Clin Exp Nephrol; 2021 Oct; 25(10):1051-1056. PubMed ID: 34224008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physiological insights into novel therapies for nephrogenic diabetes insipidus.
    Sands JM; Klein JD
    Am J Physiol Renal Physiol; 2016 Dec; 311(6):F1149-F1152. PubMed ID: 27534996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nephrogenic Diabetes Insipidus.
    Balla A; Hunyady L
    Exp Suppl; 2019; 111():317-339. PubMed ID: 31588538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vasopressin type-2 receptor and aquaporin-2 water channel mutants in nephrogenic diabetes insipidus.
    Deen PM; Knoers NV
    Am J Med Sci; 1998 Nov; 316(5):300-9. PubMed ID: 9822112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hereditary Nephrogenic Diabetes Insipidus: Pathophysiology and Possible Treatment. An Update.
    Milano S; Carmosino M; Gerbino A; Svelto M; Procino G
    Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29125546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Animal models for diabetes insipidus.
    Mahía J; Bernal A
    Handb Clin Neurol; 2021; 181():275-288. PubMed ID: 34238463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An impaired routing of wild-type aquaporin-2 after tetramerization with an aquaporin-2 mutant explains dominant nephrogenic diabetes insipidus.
    Kamsteeg EJ; Wormhoudt TA; Rijss JP; van Os CH; Deen PM
    EMBO J; 1999 May; 18(9):2394-400. PubMed ID: 10228154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A case of a novel mutant vasopressin receptor-dependent nephrogenic diabetes insipidus with bilateral non-obstructive hydronephrosis in a middle aged man: differentiation from aquaporin-dependent nephrogenic diabetes insipidus by response of factor VII and von Willebrand factor to 1-diamino-8-arginine vasopressin administration.
    Miyakoshi M; Kamoi K; Uchida S; Sasaki S
    Endocr J; 2003 Dec; 50(6):809-14. PubMed ID: 14709855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A female with X-linked Nephrogenic diabetes insipidus in a family with inherited central diabetes Insipidus: Case report and review of the literature.
    Ding C; Beetz R; Rittner G; Bartsch O
    Am J Med Genet A; 2020 May; 182(5):1032-1040. PubMed ID: 32073219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic forms of nephrogenic diabetes insipidus (NDI): Vasopressin receptor defect (X-linked) and aquaporin defect (autosomal recessive and dominant).
    Bichet DG; Bockenhauer D
    Best Pract Res Clin Endocrinol Metab; 2016 Mar; 30(2):263-76. PubMed ID: 27156763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physiopathology and diagnosis of nephrogenic diabetes insipidus.
    Devuyst O
    Ann Endocrinol (Paris); 2012 Apr; 73(2):128-9. PubMed ID: 22503803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nephrogenic diabetes insipidus.
    Bichet DG
    Am J Med; 1998 Nov; 105(5):431-42. PubMed ID: 9831428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Defective processing and trafficking of water channels in nephrogenic diabetes insipidus.
    Kamsteeg EJ; Deen PM; van Os CH
    Exp Nephrol; 2000; 8(6):326-31. PubMed ID: 11014929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.